Showing results (2201-2210 of 2,629) with videos related to

Sort By:
Pageof 263
NPJ Precision Oncology|February 21, 2023
BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) studyBlessie Elizabeth Nelson, Jason Roszik, Filip Janku, et al.
Practical Radiation Oncology|November 14, 2024
Best Practice Guidelines for Use of Reference Points in Radiation Oncology Information Systems to Aggregate Longitudinal Dosimetric DataAlon Witztum, Younes Jourani, Emily Y Hirata, et al.
Bioorganic & Medicinal Chemistry Letters|October 8, 2017
Discovery of renin inhibitors containing a simple aspartate binding moiety that imparts reduced P450 inhibitionBrian G Lawhorn, Tritin Tran, Victor S Hong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2019
Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation TrialVivek Subbiah, Pete M Anderson, Kalevi Kairemo, et al.
International Journal of Radiation Oncology, Biology, Physics|June 28, 2014
Interobserver variability in target definition for hepatocellular carcinoma with and without portal vein thrombus: radiation therapy oncology group consensus guidelinesTheodore S Hong, Walter R Bosch, Sunil Krishnan, et al.
Annals of Surgical Oncology|October 3, 2018
Are Staging Computed Tomography (CT) Scans of the Chest Necessary in Pancreatic Adenocarcinoma?Winta T Mehtsun, Fallon E Chipidza, Carlos Fernández-Del Castillo, et al.
ESMO Open|June 24, 2024
A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumorsM A Gouda, J Shunyakova, A Naing, et al.
ESMO Open|June 16, 2023
Safety and efficacy of trastuzumab biosimilar plus irinotecan or gemcitabine in patients with previously treated HER2 (ERBB2)-positive non-breast/non-gastric solid tumors: a phase II basket trial with circulating tumor DNA analysisJ Hyung, J Y Lee, J E Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2022
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung CancerD Ross Camidge, Fabrice Barlesi, Jonathan W Goldman, et al.
JCO Precision Oncology|July 14, 2022
Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced CancersMohamed A Gouda, Helen J Huang, Sarina A Piha-Paul, et al.
Pageof 263